- |||||||||| Prezista (darunavir) / J&J
Clinical, Observational data, Journal: Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection. (Pubmed Central) - Feb 3, 2021 The robustness of this digital drug development approach paired with in vitro experimentation and AI-driven optimization suggests that IDentif.AI may be clinically actionable toward current and future outbreaks. Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. (Pubmed Central) - Feb 3, 2021 Management strategies have been evolved by the recommendations of WHO, specifically important to control COVID-19 situations, in the pandemic era. This review will provide a comprehensive collection of studies to support future research and enhancement in our wisdom to combat COVID-19 pandemic and to serve humanity.
- |||||||||| Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Rebif (human IFN-?-1a) / EMD Serono
Enrollment closed: DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults (clinicaltrials.gov) - Feb 2, 2021 P3, N=3100, Active, not recruiting, This review will provide a comprehensive collection of studies to support future research and enhancement in our wisdom to combat COVID-19 pandemic and to serve humanity. Recruiting --> Active, not recruiting
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Severe hypocalcaemia in a COVID-19 female patient. (Pubmed Central) - Feb 2, 2021 She was treated with lopinavir/ritonavir, third generation cephalosporin, anticoagulant, daily high-dose calcium acetate, vitamin D3, fresh frozen plasma and oxygen therapy...In addition to inflammatory markers, in COVID-19 patients it is crucial to check the level of vitamin D and calcium. There may be a correlation between vitamin D deficiency and the severity of COVID-19 disease.
- |||||||||| Apocept (asunercept) / Apogenix, Pentaglobin (human immune globulin IV 10%) / Grifols
Trial completion date, Trial primary completion date: ACOVACT: Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (clinicaltrials.gov) - Feb 1, 2021 P2/3, N=500, Recruiting, There may be a correlation between vitamin D deficiency and the severity of COVID-19 disease. Trial completion date: Dec 2020 --> Mar 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] CASE SERIES OF SARS-COV-2 INFECTION IN STEM CELL TRANSPLANT RECIPIENTS (Hall B) - Jan 30, 2021 - Abstract #APBMT2020APBMT_21; The combination of Lopinavir/ritonavir, ribavirin, Interferonβ1b achieves rapid defervescence and clinical improvement. Like immunocompetent patients, Tocilizumab is effective in severe COVID19 even in SCT recipients However, there is delayed viral clearance in SCT recipients, probably due to impaired humoral and cell mediated immunity.
- |||||||||| Review, Journal: Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic. (Pubmed Central) - Jan 29, 2021
The other drugs such as favipiravir and lopinavir/ritonavir under the antiviral category, the angiotensin-converting enzyme 2 (the renin-angiotensin system inhibitors), remdesivir (RNA polymerase inhibitor) from antiviral category, cepharanthine from anti-inflammatory category, etc., have been pointed based on the previous literature published. Besides, the assessment of the drug repositioning candidates with the related targets is also significant for the viral mitigation.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Journal: Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. (Pubmed Central) - Jan 28, 2021 Besides, the assessment of the drug repositioning candidates with the related targets is also significant for the viral mitigation. No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patient Ritonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Observational data, Journal: Acute kidney failure in patients admitted due to COVID-19. (Pubmed Central) - Jan 28, 2021 Those who develop AKI during hospitalization display worse prognostic factors in terms of pulmonary damage, renal damage, and analytical findings. We believe that monitorization of renal markers, as well as individualized fluid management, can play a key role in AKI prevention.
- |||||||||| Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic University
Clinical, Observational data, Retrospective data, Journal: Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective. (Pubmed Central) - Jan 28, 2021 We believe that monitorization of renal markers, as well as individualized fluid management, can play a key role in AKI prevention. This pharmacovigilance surveillance study provides a unique characterization of cases in which a broad range of pharmaceutical products was reported in relation to COVID-19.
- |||||||||| dexamethasone / Generic mfg.
Review, Journal: COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. (Pubmed Central) - Jan 27, 2021 Reviewing these therapies in a historical way shows how limited evidence can drive therapy decisions. A broad summary of available evidence can assist clinicians in a return to hierarchical assessments of evidence which can lead to safer patient outcomes, improved distribution of resources, and better targets for appropriate therapy decisions.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Journal: The Relationship Between Positivity for COVID-19 RT-PCR and Symptoms, Clinical Findings, and Mortality in Turkey. (Pubmed Central) - Jan 27, 2021 Among patients presenting with suspected COVID-19 and pneumonic infiltration consistent with COVID-19 on thoracic CT, the symptoms, physical examination, total CT scores, duration of hospitalization, intensive care requirement, and mortality rate were similar between RT-PCR-positive and -negative patients. However, PCR-positive patients appeared to require more specific treatments.
- |||||||||| Trial completion date, Trial termination: RESIST-2: 2nd-line ART for HIV-2 Infection (clinicaltrials.gov) - Jan 25, 2021
P=N/A, N=152, Terminated, However, there is still a need for further molecular dynamic simulation, in vivo and in vitro studies to support these findings. Trial completion date: Jul 2022 --> May 2020 | Active, not recruiting --> Terminated; COVID-19 and Funding
- |||||||||| Intron A (interferon α-2b) / Merck (MSD), Biogen
Journal: Long-term application of hydroxychloroquine could not prevent the infection of COVID-19. (Pubmed Central) - Jan 23, 2021 Our findings did not support the use of IVIg in combination with hydroxychloroquine and lopinavir/ritonavir in treatment of severe COVID-19 cases. Long-term application of HCQ could not prevent COVID-19 infection, but whether HCQ exerts benefit to alleviation of clinical symptoms and duration of hospital stays remains to be further investigated.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: Perceptions of Romanian Physicians on Lockdowns for COVID-19 Prevention. (Pubmed Central) - Jan 23, 2021 In conclusion, initially, following only a 1 month period, Romanian physicians' intention to consider treatments such as hydroxychloroquine or lopinavir/ritonavir for COVID-19 decreased significantly. Moreover, confidence in the efficiency of available protective measures increased, and the rates of separation from household members decreased.
- |||||||||| remdesivir / Generic mfg.
Journal: Remdesivir (Veklury) for COVID-19. (Pubmed Central) - Jan 23, 2021 In this review, we focus on the biochemical and molecular mechanistic aspects of drug-related blockade of the hERG channel to provide insights into QT prolongation caused by off-label use of related drugs in COVID-19, and hope to weigh the risks and benefits when using these drugs. No abstract available
- |||||||||| favipiravir / Generic mfg.
Review, Journal: Role of favipiravir in the treatment of COVID-19. (Pubmed Central) - Jan 21, 2021 Recently, treatment guidelines from many countries and some states from India have included favipiravir in the treatment protocol. This review provides insights into the evidence-based evolving role of favipiravir in the management of COVID-19 infection with emphasis on benefits of initiating an early antiviral therapy with special focus on favipiravir, its pharmacodynamic, pharmacokinetic, in vitro, clinical data, and inclusion in the treatment protocols of COVID-19.
- |||||||||| hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Observational data, Retrospective data, Journal: Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. (Pubmed Central) - Jan 21, 2021 This review provides insights into the evidence-based evolving role of favipiravir in the management of COVID-19 infection with emphasis on benefits of initiating an early antiviral therapy with special focus on favipiravir, its pharmacodynamic, pharmacokinetic, in vitro, clinical data, and inclusion in the treatment protocols of COVID-19. Prescribing experimental therapies for COVID-19 was not associated with a reduced LOS and might have increased the pressure put on healthcare systems.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. (Pubmed Central) - Jan 21, 2021 DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Evaluation of the initial response in clinical trial efforts for COVID-19 in Brazil. (Pubmed Central) - Jan 21, 2021 The interventions evaluated during the Brazilian research response reflect those of international initiatives, but with a different distribution and a large number of studies assessing hydroxychloroquine/chloroquine. Limitations in methodological design and sample planning represent challenges that could affect the research outreach.
|